Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple myeloma biology: lessons from the 5TMM models.
Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Vanderkerken K, et al. Among authors: croucher p. Immunol Rev. 2003 Aug;194:196-206. doi: 10.1034/j.1600-065x.2003.00035.x. Immunol Rev. 2003. PMID: 12846816 Review.
The 5T2MM murine model of multiple myeloma: maintenance and analysis.
Vanderkerken K, Asosingh K, Willems A, De Raeve H, Couck P, Gorus F, Croucher P, Van Camp B. Vanderkerken K, et al. Among authors: croucher p. Methods Mol Med. 2005;113:191-205. doi: 10.1385/1-59259-916-8:191. Methods Mol Med. 2005. PMID: 15968104
Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K, Van Valckenborgh E, Van Riet I, Van Camp B, Horuk R, Croucher P, Vanderkerken K. Menu E, et al. Among authors: croucher p. Clin Exp Metastasis. 2006;23(5-6):291-300. doi: 10.1007/s10585-006-9038-6. Epub 2006 Nov 3. Clin Exp Metastasis. 2006. PMID: 17086356
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.
Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, Vanderkerken K. Menu E, et al. Among authors: croucher p. Int J Cancer. 2007 Oct 15;121(8):1857-61. doi: 10.1002/ijc.22845. Int J Cancer. 2007. PMID: 17546599 Free article.
Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI. Vanderkerken K, et al. Cancer Res. 2007 May 15;67(10):4572-7. doi: 10.1158/0008-5472.CAN-06-4361. Epub 2007 May 10. Cancer Res. 2007. PMID: 17495322
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K. Deleu S, et al. Among authors: croucher p. Cancer Res. 2009 Jul 1;69(13):5307-11. doi: 10.1158/0008-5472.CAN-08-4472. Epub 2009 Jun 16. Cancer Res. 2009. PMID: 19531653
230 results